Related Experiment Videos
Immunoadsorption therapy in Guillain-Barré syndrome
K Hirai1, M Kihara, F Nakajima
1Division of Pediatrics, Social Insurance Kyoto Hospital, Japan.
Pediatric Neurology
|July 31, 1998
Summary
Guillain-Barré syndrome (GBS) in a child rapidly improved with immunoadsorption therapy targeting anti-GM1 antibodies. This treatment effectively reduced antibody levels and restored clinical and electrophysiologic function.
Area of Science:
- Neurology
- Immunology
- Infectious Diseases
Background:
- Guillain-Barré syndrome (GBS) is an autoimmune disorder often triggered by infections.
- Campylobacter jejuni enteritis is a common antecedent infection associated with GBS.
- Anti-ganglioside antibodies, particularly anti-GM1, are implicated in GBS pathogenesis.
Observation:
- A 12-year-old boy presented with rapid onset GBS following C. jejuni enteritis.
- Electrophysiology revealed dominant demyelination with elevated anti-C. jejuni and anti-GM1 (IgG and IgM) antibodies.
- The patient received three sessions of immunoadsorption using a tryptophan-immobilized column.
Findings:
- Clinical and electrophysiologic recovery was observed shortly after immunoadsorption therapy.
- Serum levels of IgG and IgM anti-GM1 antibodies significantly decreased post-treatment.
- Hemodynamic stability was maintained with albumin and etilefrine hydrochloride during therapy.
Implications:
- Immunoadsorption therapy is a viable treatment option for anti-GM1 antibody-associated GBS.
- This approach offers a targeted strategy for removing pathogenic antibodies in GBS.
- Early consideration of immunoadsorption may improve outcomes in pediatric GBS cases.